Metother (Methotrexate)

Methotrexate blocks dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for purine and thymidylate synthesis. This limits DNA, RNA and protein production, which suppresses rapidly dividing immune cells and tumour cells, providing both immunosuppressive and anticancer effects.

The dose of Metother is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber will calculate the appropriate amount for each patient.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnant women because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To order Metother, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with biologic agents such as TNF‑alpha inhibitors, methotrexate (Metother) is a small‑molecule drug that can be administered by subcutaneous injection and is generally less expensive. It has a well‑established efficacy profile but may require more laboratory monitoring for hepatic and haematologic toxicity.

Metother should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours and keep the product in its original packaging.

Metother is supplied as a sterile solution for subcutaneous injection. A healthcare professional injects the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, using aseptic technique. Patients should be instructed on rotation of injection sites to minimise local reactions.

The most serious adverse events include severe hepatotoxicity (liver fibrosis or failure), pulmonary fibrosis, life‑threatening infections due to immunosuppression, and bone‑marrow failure leading to aplastic anaemia or pancytopenia. Prompt monitoring and early detection are essential to mitigate these risks.

Metother is contraindicated in pregnant or breastfeeding women, patients with severe hepatic impairment, uncontrolled infections, or known hypersensitivity to methotrexate. Caution is also advised for individuals with significant renal dysfunction, existing bone‑marrow disorders, or those receiving other potent immunosuppressants.